𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

✍ Scribed by Vahakn B. Shahinian; Yong-fang Kuo; Jean L. Freeman; Eduardo Orihuela; James S. Goodwin

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
228 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Bone fractures associated with luteinizi
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
✍ Murphy F. Townsend; W. Holt Sanders; Robert O. Northway; Sam D. Graham Jr. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 2 views

## Background: Luteinizing hormone-releasing hormone agonists (lhrh-a) have become an established treatment for certain patients with prostate carcinoma. lhrh-a are known to decrease bone mineral density. the purpose of this study was to determine the risk of bone fracture in men receiving lhrh-a f

Changes in bone mineral density and body
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma
✍ Hang Lee; Katelyn McGovern; Joel S. Finkelstein; Matthew R. Smith πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Initial treatment with a gonadotropin‐releasing hormone (GnRH) agonist increases fat mass, decreases lean body mass, and decreases bone mineral density (BMD) in men with prostate carcinoma. To the authors' knowledge, little is known regarding either the long‐term effects

The use of treatments for erectile dysfu
The use of treatments for erectile dysfunction among survivors of prostate carcinoma
✍ Leslie R. Schover; Rachel T. Fouladi; Carla L. Warneke; Leah Neese; Eric A. Klei πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 1 views

## Background: The objectives of this survey were to describe the prevalence of using a treatment for erectile dysfunction (ed) among men after therapy for localized prostate carcinoma and to construct models explaining the variance in trying a treatment, treatment success, and adherence to treatme

The addition of chemotherapy to hormonal
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
✍ R. P. Gibbons; S. Beckley; M. F. Brady; T. M. Chu; J. B. Dekernion; C. Dhabuwala πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 674 KB

## Abstract Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 a